Memantine Hydrochloride Tablet, Film Coated
Product Images NDC 68180-229

17 FDA label images from Lupin Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 68180-229). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (392d48fd 7c93 40f3 9ab0 D0f304b7e439 01)

Structure (392d48fd 7c93 40f3 9ab0 D0f304b7e439 01)
Chemical structure of memantine hydrochloride, showing a bicyclic cage-like framework with amino (NH2) and methyl (CH3) substituents, illustrating the molecular arrangement of the active ingredient.*
FDA Label Image

Figure 1 (392d48fd 7c93 40f3 9ab0 D0f304b7e439 02)

Figure 1 (392d48fd 7c93 40f3 9ab0 D0f304b7e439 02)
Line graph depicting the mean change from baseline in ADCS-ADL score over 28 weeks of treatment comparing Memantine hydrochloride and placebo groups. The x-axis represents weeks of treatment (0, 4, 12, 28), and the y-axis shows the mean change including SEM. The plot includes markers for Memantine (circles) and placebo (squares), illustrating clinical improvement or decline over time.*
FDA Label Image

Figure 2 (392d48fd 7c93 40f3 9ab0 D0f304b7e439 03)

Figure 2 (392d48fd 7c93 40f3 9ab0 D0f304b7e439 03)
A line graph showing the cumulative percentage of patients versus ADCS-ADL change from baseline. Two lines compare Placebo and Memantine groups, with Memantine showing a higher cumulative percentage of patients experiencing a greater change below baseline.*
FDA Label Image

Figure 3 (392d48fd 7c93 40f3 9ab0 D0f304b7e439 04)

Figure 3 (392d48fd 7c93 40f3 9ab0 D0f304b7e439 04)
A line graph showing mean change from baseline in SIB score over 28 weeks of treatment comparing placebo and Memantine groups. The x-axis represents weeks of treatment (0, 4, 12, 28), and the y-axis shows mean change from baseline with error bars. The Memantine group shows improvement near baseline early, with gradual decline, while the placebo group shows continuous decline toward clinical decline.*
FDA Label Image

Figure 4 (392d48fd 7c93 40f3 9ab0 D0f304b7e439 05)

Figure 4 (392d48fd 7c93 40f3 9ab0 D0f304b7e439 05)
A line graph showing the cumulative percentage of patients over a range of values, comparing Memantine versus placebo groups. The graph includes two plotted lines with Memantine indicated by circles and placebo by squares, demonstrating a higher cumulative percentage of patients in the Memantine group across the range.*
FDA Label Image

Figure 5 (392d48fd 7c93 40f3 9ab0 D0f304b7e439 06)

Figure 5 (392d48fd 7c93 40f3 9ab0 D0f304b7e439 06)
A line graph depicting mean change from baseline in ADCS-ADL score over 24 weeks of treatment comparing Memantine/Donepezil and Placebo/Donepezil groups. The graph shows clinical decline and improvement trends with data points and error bars at intervals during treatment weeks.*
FDA Label Image

Figure 6 (392d48fd 7c93 40f3 9ab0 D0f304b7e439 07)

Figure 6 (392d48fd 7c93 40f3 9ab0 D0f304b7e439 07)
A cumulative percentage of patients chart illustrating changes in ADCS-ADL from baseline for two groups: Placebo/Donepezil and Memantine/Donepezil. The x-axis represents the ADCS-ADL change from baseline, and the y-axis shows the cumulative percentage of patients. The chart compares the distribution of patient responses between the two treatment groups.*
FDA Label Image

Figure 7 (392d48fd 7c93 40f3 9ab0 D0f304b7e439 08)

Figure 7 (392d48fd 7c93 40f3 9ab0 D0f304b7e439 08)
A line chart comparing the mean change from baseline in SIB scores over 24 weeks of treatment between two groups: Placebo/Donepezil and Memantine/Donepezil. The x-axis shows weeks of treatment, and the y-axis shows mean change (± SEM). The chart indicates clinical improvement above the zero line and clinical decline below it, with Memantine/Donepezil showing greater clinical improvement over time than Placebo/Donepezil.*
FDA Label Image

Figure 8 (392d48fd 7c93 40f3 9ab0 D0f304b7e439 09)

Figure 8 (392d48fd 7c93 40f3 9ab0 D0f304b7e439 09)
A cumulative percentage of patients chart showing SIB (Severe Impairment Battery) change from baseline on the x-axis and cumulative percentage of patients on the y-axis. The chart compares two groups: Placebo/Donepezil and Memantine/Donepezil, illustrating their relative effectiveness across a range of SIB change scores.*
FDA Label Image

Image (A45cb12c 3184 4289 A011 9f0a31b19099 100 1)

Image (A45cb12c 3184 4289 A011 9f0a31b19099 100 1)
Memantine hydrochloride film-coated tablets in 10 mg strength are shown. The image displays two round, biconvex tablets, brownish in color with a score line across the middle. No packaging or labeling text is visible beyond the tablet form and color.*
FDA Label Image

Image (A45cb12c 3184 4289 A011 9f0a31b19099 114 1)

Image (A45cb12c 3184 4289 A011 9f0a31b19099 114 1)
Memantine hydrochloride 10 mg film-coated tablets packaging display. The image shows seven round, black film-coated tablets arranged in a flower shape on a white background. There is no visible text or branding on the tablets.*
FDA Label Image

5 mg (392d48fd 7c93 40f3 9ab0 D0f304b7e439 10)

5 mg (392d48fd 7c93 40f3 9ab0 D0f304b7e439 10)
Label for Memantine Hydrochloride Tablets USP 5 mg film-coated tablets, packaged as 60 tablets. The label includes manufacturing information for Lupin Pharmaceuticals, Inc., USA, and Lupin Limited, India, with storage instructions and a barcode. The product is prescription-only and directs pharmacists to provide patient information separately.*
FDA Label Image

Container Label 5 mg (392d48fd 7c93 40f3 9ab0 D0f304b7e439 11)

Container Label 5 mg (392d48fd 7c93 40f3 9ab0 D0f304b7e439 11)
Memantine Hydrochloride Tablets USP 5 mg film-coated tablets package label, containing 60 tablets. The label includes storage instructions and prescribing information notes. Manufactured for Lupin Pharmaceuticals, Inc., Naples, FL, and manufactured by Lupin Limited, Goa, India. The label features the NDC 68180-229-07 and Lupin branding.*
FDA Label Image

Carton Label 5 mg (392d48fd 7c93 40f3 9ab0 D0f304b7e439 12)

Carton Label 5 mg (392d48fd 7c93 40f3 9ab0 D0f304b7e439 12)
Packaging label for Memantine Hydrochloride Tablets USP, 5 mg, film-coated oral tablets. The label shows the product name prominently along with strength and instructions for pharmacists to dispense with patient information leaflet. The package contains 100 tablets arranged in 10 unit-dose packs. The labeler is Lupin Pharmaceuticals, Inc., with manufacturing information for Lupin Limited, India. The NDC number 68180-229-13 is visible.*
FDA Label Image

10 mg (392d48fd 7c93 40f3 9ab0 D0f304b7e439 15)

10 mg (392d48fd 7c93 40f3 9ab0 D0f304b7e439 15)
Label for Memantine Hydrochloride Tablets USP 10 mg film-coated tablets, available in a 60-tablet package. The label includes storage instructions and a note to dispense with a patient information leaflet. It indicates the product is Rx only and manufactured by Lupin Pharmaceuticals, Inc. in the USA and Lupin Limited in India.*
FDA Label Image

Container Label 10 mg (392d48fd 7c93 40f3 9ab0 D0f304b7e439 13)

Container Label 10 mg (392d48fd 7c93 40f3 9ab0 D0f304b7e439 13)
Memantine Hydrochloride Tablets USP 10 mg film-coated tablets carton label from Lupin Pharmaceuticals, Inc. The label shows an NDC of 68180-230-07 for a 60 tablet bottle. The label includes storage instructions, manufacturer details, and a barcode.*
FDA Label Image

Carton Label 10 mg (392d48fd 7c93 40f3 9ab0 D0f304b7e439 14)

Carton Label 10 mg (392d48fd 7c93 40f3 9ab0 D0f304b7e439 14)
Packaging label for Memantine Hydrochloride Tablets USP 10 mg film-coated oral tablets by Lupin Pharmaceuticals, Inc. The label indicates 100 tablets packaged as 10 x 10 unit-dose. It includes storage instructions, pharmacist dispensing advice, and manufacturer details for Lupin Pharmaceuticals and Lupin Limited. The NDC code 68180-230-13 is displayed along with a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.